EP3526325A2 - Combinaison de protéases orthogonales dédoublées présentant des domaines de dimérisation permettant un assemblage - Google Patents
Combinaison de protéases orthogonales dédoublées présentant des domaines de dimérisation permettant un assemblageInfo
- Publication number
- EP3526325A2 EP3526325A2 EP17794772.8A EP17794772A EP3526325A2 EP 3526325 A2 EP3526325 A2 EP 3526325A2 EP 17794772 A EP17794772 A EP 17794772A EP 3526325 A2 EP3526325 A2 EP 3526325A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- proteases
- split
- protease
- orthogonal
- dimerization domains
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108091005804 Peptidases Proteins 0.000 title claims abstract description 225
- 239000004365 Protease Substances 0.000 title claims abstract description 225
- 102000035195 Peptidases Human genes 0.000 title claims abstract description 121
- 238000006471 dimerization reaction Methods 0.000 title claims abstract description 87
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims abstract description 104
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 98
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 90
- 238000003776 cleavage reaction Methods 0.000 claims abstract description 59
- 230000007017 scission Effects 0.000 claims abstract description 59
- 239000000126 substance Substances 0.000 claims abstract description 16
- 150000001413 amino acids Chemical class 0.000 claims abstract description 10
- 210000004027 cell Anatomy 0.000 claims description 84
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 45
- 230000000694 effects Effects 0.000 claims description 39
- 230000019491 signal transduction Effects 0.000 claims description 19
- 230000008859 change Effects 0.000 claims description 18
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 14
- 108010027179 Tacrolimus Binding Proteins Proteins 0.000 claims description 13
- 102000018679 Tacrolimus Binding Proteins Human genes 0.000 claims description 13
- 102000004190 Enzymes Human genes 0.000 claims description 12
- 108090000790 Enzymes Proteins 0.000 claims description 12
- 230000004913 activation Effects 0.000 claims description 12
- 241000723811 Soybean mosaic virus Species 0.000 claims description 11
- 102100026280 Cryptochrome-2 Human genes 0.000 claims description 8
- 101000855613 Homo sapiens Cryptochrome-2 Proteins 0.000 claims description 8
- 238000013518 transcription Methods 0.000 claims description 7
- 230000035897 transcription Effects 0.000 claims description 7
- 230000003834 intracellular effect Effects 0.000 claims description 6
- 238000002604 ultrasonography Methods 0.000 claims description 6
- 241000196324 Embryophyta Species 0.000 claims description 5
- 241000282414 Homo sapiens Species 0.000 claims description 5
- 210000005260 human cell Anatomy 0.000 claims description 5
- 239000002207 metabolite Substances 0.000 claims description 4
- 230000001960 triggered effect Effects 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 3
- 239000005556 hormone Substances 0.000 claims description 3
- 229940088597 hormone Drugs 0.000 claims description 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 2
- 210000002569 neuron Anatomy 0.000 claims description 2
- 230000003204 osmotic effect Effects 0.000 claims description 2
- 230000028327 secretion Effects 0.000 claims description 2
- 241000894006 Bacteria Species 0.000 claims 1
- 241000233866 Fungi Species 0.000 claims 1
- 210000004102 animal cell Anatomy 0.000 claims 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 229930000044 secondary metabolite Natural products 0.000 claims 1
- 239000012634 fragment Substances 0.000 abstract description 30
- 230000015572 biosynthetic process Effects 0.000 abstract description 8
- 230000001404 mediated effect Effects 0.000 abstract description 6
- 230000001225 therapeutic effect Effects 0.000 abstract description 5
- 235000019419 proteases Nutrition 0.000 description 93
- 108060001084 Luciferase Proteins 0.000 description 48
- 239000005089 Luciferase Substances 0.000 description 47
- 238000004803 parallel plate viscometry Methods 0.000 description 36
- 229920000553 poly(phenylenevinylene) Polymers 0.000 description 36
- 108010076818 TEV protease Proteins 0.000 description 26
- 108020004414 DNA Proteins 0.000 description 21
- 102000004196 processed proteins & peptides Human genes 0.000 description 21
- 230000004927 fusion Effects 0.000 description 19
- 239000013612 plasmid Substances 0.000 description 18
- 125000004122 cyclic group Chemical group 0.000 description 17
- 230000006870 function Effects 0.000 description 16
- 102000039446 nucleic acids Human genes 0.000 description 15
- 108020004707 nucleic acids Proteins 0.000 description 15
- 150000007523 nucleic acids Chemical class 0.000 description 15
- 238000000034 method Methods 0.000 description 14
- 239000003446 ligand Substances 0.000 description 13
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 13
- 229960002930 sirolimus Drugs 0.000 description 13
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 13
- 102100038242 Replication initiator 1 Human genes 0.000 description 12
- 108091023040 Transcription factor Proteins 0.000 description 11
- 102000040945 Transcription factor Human genes 0.000 description 11
- 230000027455 binding Effects 0.000 description 10
- 210000004899 c-terminal region Anatomy 0.000 description 10
- 229940088598 enzyme Drugs 0.000 description 10
- 230000001939 inductive effect Effects 0.000 description 10
- 229920001184 polypeptide Polymers 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 9
- 230000001908 autoinhibitory effect Effects 0.000 description 8
- 230000004807 localization Effects 0.000 description 7
- 230000011664 signaling Effects 0.000 description 7
- 101800004193 Peptide P3 Proteins 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 238000003780 insertion Methods 0.000 description 6
- 230000037431 insertion Effects 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 241000723790 Tobacco vein mottling virus Species 0.000 description 5
- 230000003197 catalytic effect Effects 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- 230000005540 biological transmission Effects 0.000 description 4
- 230000036755 cellular response Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 230000017730 intein-mediated protein splicing Effects 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 230000014616 translation Effects 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 108700026244 Open Reading Frames Proteins 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 230000004481 post-translational protein modification Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000008054 signal transmission Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 230000001052 transient effect Effects 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 238000007399 DNA isolation Methods 0.000 description 2
- 230000004568 DNA-binding Effects 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 108090000331 Firefly luciferases Proteins 0.000 description 2
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 2
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 2
- 241000424623 Nostoc punctiforme Species 0.000 description 2
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 108010013829 alpha subunit DNA polymerase III Proteins 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 108091006047 fluorescent proteins Proteins 0.000 description 2
- 102000034287 fluorescent proteins Human genes 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 102000006240 membrane receptors Human genes 0.000 description 2
- 108020004084 membrane receptors Proteins 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 108020001580 protein domains Proteins 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 230000006337 proteolytic cleavage Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 239000012096 transfection reagent Substances 0.000 description 2
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108010075254 C-Peptide Proteins 0.000 description 1
- 102000000584 Calmodulin Human genes 0.000 description 1
- 108010041952 Calmodulin Proteins 0.000 description 1
- 102000003952 Caspase 3 Human genes 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 230000007023 DNA restriction-modification system Effects 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 108010068250 Herpes Simplex Virus Protein Vmw65 Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 108010076039 Polyproteins Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 241000242743 Renilla reniformis Species 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108700010756 Viral Polyproteins Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940054733 arestin Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 210000004900 c-terminal fragment Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000000447 dimerizing effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000005734 heterodimerization reaction Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- GLMUAFMGXXHGLU-VQAITOIOSA-N minocycline hydrochloride Chemical compound [H+].[Cl-].C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O GLMUAFMGXXHGLU-VQAITOIOSA-N 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000004898 n-terminal fragment Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 230000008723 osmotic stress Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 244000000003 plant pathogen Species 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 108020001775 protein parts Proteins 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000037425 regulation of transcription Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 230000001718 repressive effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
- C12N9/506—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses derived from RNA viruses
Definitions
- the invention relates to a combination of two or more orthogonal split proteases with dimerization domains which allow the assembly of split proteases and to the cells which contain combinations of orthogonal split proteases in combination with target protein.
- Activation of selected cells at a given time and space and the precise control of the cell response to activation with one or more input signals is an important technological problem. Activation can be performed by chemical activators, change in temperature and pH with electrodes or light. Cell activation is also possible with indirect or direct mechanical stimuli such as touch, shear force, fluid flow, hypo- and hyperosmotic stress, and ultrasound.
- synthetic biology often employs artificial signal cascades and logic circuits. Usually, these logical circuits are based on the regulation of transcription and protein translation, which is a relatively slow process, since transcription and translation is required, which means that the response has a delay of more than a few dozen minutes. Faster signaling in cells takes place through posttranslational change of proteins (Olson & Tabor 2012), such as phosphorylation, ubiquitination and proteolytic cleavage.
- proteolysis has already been described as a mechanism for signal transmission, with three known modes of control of protease activity known: autoinhibitor control, proximity sensor and split protease.
- the autoinhibitory peptide is a short amino acid sequence that binds to the active site of the protease, thereby preventing binding of the target substrate. If such autoinhibitory peptide is attached to protease via the cleavage site for the second protease, the activity of the first protease becomes dependent on the activity of the other. For example, a TVMV protease activated by thrombin cleavage was prepared, as well as a HCV protease activated by cleavage with the TVMV protease (Stein & Alexandrov 2014).
- a protease can also be prepared in such a way, so that the binding of the autoinhibitory peptide to the active site is dependent on the presence of the ligand.
- the TVMV protease was prepared, which either activated or deactivated in the presence of a short peptide ligand (Stein & Alexandrov 2014).
- the proximity of the sensor and it's substrate is a way of controlling the activity of the protease, based on the control over the colocation of protease and its substrate.
- cleavage with TEV protease depends on the external signal via the protease linked to the membrane receptor (GPCR), while the luciferase is bound to the receptor (arestin) which binds to the membrane receptor only in the presence of an external ligand, for example a neurotransmitter or hormone, wherein the protease bound to the GPCR triggers the proteolytic splitting of the reporter (Eishingdrelo et al., 2011).
- the autoinhibitory proteases with HCV and TVMV described above were enclosed in a proximity sensor by binding them to the FKBP and FRB domains (Stein & Alexandrov 2014). These domains are linked in the presence of rapamycin, which also brings the proteases to close proximity. If one of the proteases in the binding peptide between the enzyme and the autoinhibitory peptide contains a target cleavage site for the second protease, their immediate proximity allows the autoinhibitory peptide to be disconnected and thereby the system is activated.
- the third method of induction of protease with ligand, split protease has been described so far only for the TEV protease (Wehr et al., 2006).
- the protease sequence was split into the N-terminal and C- terminal fragments attached to the rapamycin-binding domains of FKBP and FRB. In the presence of rapamycin, these domains connect and being both halves of split proteases in close proximity which allows the protease to take up its active form.
- Each of the coiled coils contains a cleavage site fused with an autoinhibitory peptide which inhibits coiled coil dimerization. After both autoinhibitory peptides have been cleavage by a protease (TEV and caspase-3 have been used) dimerization is enabled and an output signal is detected.
- the described reporter acts as a logic operation AND.
- Protease TEV belongs to the family of potivirus proteases. These viruses are plant pathogens whose genome is transcribed into a single polyprotein, a part of which is a core inclusion domain (NIa) that splits the viral polyprotein into individual functional subunits.
- TEV protease In addition to the TEV protease, PPV, TVMV, SbMV, SuMMV and other protease viruses are known and characterized in this family, and target sequences are also known which are effectively cleaved by these proteases (JM Adams et al., 2005; MJ Adams et al. 2005; Ghabrial et al., 1990; Tozser et al., 2005). Some of these proteases have already been shown to be orthogonal (Fernandez-Rodriguez & Voigt 2016). Nevertheless, only the TEV protease appears as a widely used synthesis-biological tool and is the only potivirus protease that has been prepared so far in split form.
- RAFT1 a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell, 78(1), pp.35-43. Sabers, CJ. et al., 1995. Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. The Journal of biological chemistry, 270(2), pp.815-822.
- the invention solves the above-described problems of lack of fast orthogonal signaling pathways based on posttranslational modification of proteins, which was achieved by the introduction of a combination of at least two orthogonal split proteases in association with dimerization domains that allow the reconstitution of split proteases into cells.
- the invention relates to a combination of orthogonal split proteases that recognize a target sequence comprising at least 6 amino acids associated with dimerization domains that allow for the reconstitution of split proteases.
- At least two orthogonal proteases are prepared as split fragments in association with dimerization domains, where dimerization can be inducible by light, chemical or other input signal.
- Proteases cleave one or more target proteins that contain a target sequence for one or more orthogonal proteases and act as further mediators of the signal, the reporting protein, or therapeutic proteins. With appropriately selected target proteins, logical circuits mediated by proteases can be prepared.
- the invention also relates to cells that contain a combination of orthogonal split proteases in association with dimerization domains and target proteins containing the appropriate cleavage sites identified by individual proteases when they are assembled.
- a complementary pair of dimerization domains allows for the assembly of individual split proteases.
- the complementary pair can be formed spontaneously or with the help of an initiator, which can be intracellular or external, such as light, pH, temperature, mechanical stress, chemical signal.
- Dimerization domains can be different for each type of split protease or are the same for all orthogonal proteases.
- Reconstituted protease acts on a target protein containing the cleavage site for the selected protease which may be endogenous or transgenetically inserted into a reporter or other intermediary signal.
- a signaling system based on split proteases contains at least two split proteases.
- Each of the split proteases in the system may have its target protein (mediator or reporter), but two or more proteases may function on the same target protein if it contains various identifiable cleavage sites.
- the concept of the invention is presented graphically in Figure 1.
- Transmission of the signal through split proteases may trigger or stop the transcription of selected genes or secretion of selected molecules, which is useful for the treatment of nervous system disorders, hormonal disorders, for metabolic and blood flow restrictions and other diseases.
- the invention is useful for controlling the action of human, animal or plant cells, for transmitting the signal to other cells, for secreting peptides, proteins and other molecules, to detect a combination of two or more chemical, light or mechanical signals.
- Figure 1 A schematic diagram of a signal system with orthogonal split proteases associated with dimerization domains that can be activated via an inductor that may be intracellular or external.
- the inactive split protease is assembled into the active protease and cleaves the target protein substrate, which leads to a change in the target protein, which may be a reporter, a different protease, an inactive enzyme, etc.
- Each orthogonal split protease can have its own dimerization domains, thus various inductors can activate various orthogonal proteases, and in this way lead to different cell responses via logic operations,.
- Proteases break down the target protein that leads to the continuation of the signal pathway (for example, transcriptional regulation) or represents an output signal (for example a fluorescent protein). If the target protein contains recognizable sites for cleavage with various proteases, the signal transfer with proteases can act as a logic circuit.
- Figure 2 Orthogonality of selected proteases. The activity of each protease is shown as a cyclic luciferase activity with a marked cleavage site for the protease. The target sequences for cleavage of each protease are shown.
- Figure 3 Inducibility of selected proteases. The activity of each protease is shown as cyclic luciferase activity with the appropriate cleavage site for the selected protease. A) Induction of split proteases with rapamycin. B) Induction of the split TEV protease with blue light. C) Induction of split PPV protease with blue light.
- FIG. 4 Activation of orthogonal signaling pathways mediated by TEV and PPV proteases.
- TEV protease cleaves the transcription factor, which increases the expression of the mCitrin reporter.
- PPV protease activates the cyclic luciferase reporter via cleavage.
- the activity of the reporter is high only when stimulated with light that activates the TEV protease, but not with stimulation with rapamycin that activates PPV protease or with rapamycin and light at the same time.
- the invention relates to a combination of two or more orthogonal split proteases that recognize a target sequence comprising of at least 6 amino acids with dimerization domains that enable the functional reconstitution of protease activity, as well as target proteins with a target sequence recognized by the proteases.
- the combination of orthogonal split proteases with dimerization domains includes, according to the invention, :
- At least two split proteases each of which is expressed as a minimal of two split protein fragments and which are selected preferentially from the NIa family of potivirus proteases, preferentially proteins SuMMV, SbMV, PPV and TEV; preferentially at least one of the split proteases is composed of two proteins with the protein sequence of SEQ ID 4 and SEQ ID 6, SEQ ID. 10 and SEQ ID. 12, SEQ ID. 16 and SEQ ID. 18, SEQ ID. 22 and SEQ ID. 24, or their homologs that have at least 30% similarity of the amino acid sequence
- dimerization domains that assemble spontaneously and are selected from domains that spontaneously form dimers, preferentially dimeric proteins, helical coils and beta structures, all of which have, preferentially, orthogonal properties
- the dimerization of the domains is triggered by (i) an intracellular signal such as: a change in the concentration of a metabolite or a secondary signaling molecule, a change in the enzyme activity, or with (ii) an external signal such as temperature change, pH value, mechanical stress, change in osmotic pressure, ultrasound, light, chemical or biological signal
- dimerization domains preferentially coiled helices, light inducible domains; preferentially CRY2 and CIBN, chemically inducible domains; preferentially FKBP and FRB, or calcium-dependent domains; preferably calmodulin and Ml 3, in fusion with split protease fragments that can form homodimers, heterodimers or which form a covalent bond as a result of self cleavage (inteins) and whose dimerization is dependent on the input signal, the input signal being a mechanical stimulus; preferably ultrasound or touch, a light signal, a chemical ligand; preferably rapamycin, or another physiologically relevant signal, such as proteolytic cleavage
- At least one protein comprising at least one recognizable cleavage site for at least one of the split proteases and may form the next sequential step in a signaling pathway, for instance a transcriptional regulator, or which functions as a therapeutic target, a therapeutic protein or peptide or a reporter protein, preferably luciferase, SEAP or a fluorescent protein
- Optionally includes an arbitrary marker sequence for protein detection or affinity chromatography (e.g., HIS and AU1 markers).
- an arbitrary marker sequence for protein detection or affinity chromatography e.g., HIS and AU1 markers.
- the invention relates to cells that contain the above-described orthogonal signaling pathways and in which the signal path leads to a response that can be expressed in several ways, such as (i) release of endogenous cell metabolites, peptides or proteins (e.g., hormones), ( ii) releasing exogenous metabolites, peptides or proteins, preferably therapeutic proteins, (iii) modifying the activity of endogenous or exogenous proteins (preferably enzymes) in the cell, or (iv) controlling the expression of genes.
- the invention relates to cells selected from bacterial or eukaryotic cells, plant cells or human cell lines, preferentially the invention relates to mammalian cells and human cell lines, for example to neurons or other nervous system cells, T lymphocytes or other immune cells or pancreatic beta cell.
- split protease refers to two or more polypeptides ("fragments") derived from the protease sequence, each of them being equal to one part of the whole protease.
- fragments alone are not catalyticaly active.
- the formation of a proteolytically active complex requires the interaction of protease fragments; this process is termed "reconstitution”.
- Protease fragments are selected so that reconstitution cannot occur between them without the aid of additional dimerization domains, which are expressed in fusion with protease fragments in the form of a chimeric protein.
- chimeric protein means a protein or polypeptide consisting of sequences derived from non-native proteins and formed upon the translation of a chimeric nucleic acid that combines the records for the individual domains of non-native proteins composed to form a single open reading frame.
- dimerization domain refers to protein domains that connect independently or in the presence of a ligand to one another through covalent or non-covalent interactions.
- homodimerization refers to domains that connect to other domains of the same type, and the term “heterodimerization” refers to domains that connect to other domains of a different type.
- constitutive dimerization domains refers to dimerization domains that connect themselves independently, such as, for example, coiled coils, and the term “inducible dimerization domain” refers to dimerization domains that merge only in the presence of a dimerization signal.
- signal refers to a measurable change within a cell or in its environment.
- input signal refers to a change that triggers a signalling pathway
- output signal refers to a change that occurs as a result of the signalling pathway.
- An input signal may be part of an endogenous signalling pathway or is triggered exogenously and causes a physiological response of the cell, for example, a change in the concentration of a secondary signalling molecule, such as calcium, or a dimerization signal that affects the dimerization of endogenous or exogenous dimerization domains.
- dimerization signal refers to ligands, light and mechanical stimuli, pH changes, post- translational modification of dimerization domains, change in the secondary signalling molecule concentration, or alteration of the transmembrane potential, which cause the dimerization of domains that do not have intrinsic affinity with each other and cannot be connected independently in the absence of a dimerization ligand or signal.
- mechanical signal refers to all kinds of mechanical disturbances / forces such as ultrasound, touch, osmotic stress and friction due to the flow of fluid that affect the cells or the cell membrane.
- the mechanical signal can be generated by the pressure of a particular solid object, liquid, or other cells on the cell membranes, due to the gravitational, centrifugal, shear or other direct force, or due to indirect forces that induce action on the cell membrane, such as osmosis, stretching or shrinking of the membrane due to temperature or other factors.
- ultrasonic refers to acoustic waveforms with a frequency between about 20 kHz to about 15 MHz, generated by a device with which the strength or sound amplitude, frequency in combination with a suitable converter, and a time dependency regime for ultrasonic pulses can be controlled.
- the term »chemical signal « used herein refers to a change in ligand concentration.
- the term »ligand « used herein refers to short biopolymers, organic or inorganic molecules and ions that can bind to proteins, preferably to dimerization domains.
- light signal refers to electromagnetic waves in the visible range (wavelengths between 400 and 700 nm), near infrared (wavelengths between 700 nm and 4 ⁇ ) or ultraviolet (wavelengths between 10 nm and 400 nm), which may cause conformational or chemical changes in biological molecules, preferably dimerization domains or their ligands.
- signal pathway refers to one or more events in a cell that may comprise ligand binding, dimerization of proteins or peptides, influx of secondary messenger molecules, alteration of the transmembrane potential, enzyme-catalyzed reaction or other cell changes, and which are triggered by an input signal, and which produces an output signal as its final product.
- orthogonal proteases means two or more proteases that differ in the order of the target substrate so that none of the orthogonal proteases do not split the target substrate of the second orthogonal protease.
- linker peptide refers to amino acid sequences whose role is to separate the individual domains of the assembled protein and to enable their proper spatial orientation.
- the role of the linker peptide in the fusion protein can also be used as a space to include the insertion of the cleavage site, the posttranslational modification site, the marker sequence, or the localization signal.
- linker peptides The position of linker peptides, marker sequences, cleavage sites, and localization signals is arbitrary, although they must be posited in a way that allows for the functional expression of the protein and preserves the functions for which these amino acid sequences have been selected and which are well known to experts in the field.
- cell refers to an eukaryotic cell, a cellular or multicellular organism (cell line) cultured as a single cell entity that has been used as a recipient of nucleic acids and includes the daughter cells of the original cell that has been genetically modified by the inclusion of nucleic acids.
- the term refers primarily to cells of higher developed eukaryotic organisms, preferably vertebrates, preferably mammals.
- Genetically modified host cell (also “recombinant host cell”) is a host cell into which the nucleic acid has been introduced.
- the eukaryotic genetically modified host cell is formed in such a way that a suitable nucleic acid or recombinant nucleic acid is introduced into the appropriate eukaryotic host cell.
- the invention hereafter includes host cells and organisms that contain a nucleic acid according to the invention (transient or stable) bearing the operon record according to the invention.
- Suitable host cells are known in the field and include eukaryotic cells. It is known that proteins can be expressed in cells of the following organisms: human, rodent, cattle, pork, poultry, rabbits and the like. Host cells may include cultured cell lines of primary or immortalized cell lines.
- nucleic acids refers to a polymeric form of nucleotides (ribonucleotides or deoxyribonucleotides) of any length and is not limited to single, double or higher chains of DNA or RNA, genomic DNA, cDNA, DNA-RNA hybrids, or polymers with a phosphorothioate polymer backbone made from purine and pyrimidine bases or other natural, chemical or biochemically modified, synthetic or derived nucleotide bases.
- »polypeptide«, »protein « , »peptide «, used herein refers to the polymeric forms of amino acids of any length.
- «functional polypeptide* used herein refers to a polypeptide form of any length of amino acids which expresses any function, for instance: structure formation, localizing to a specific location, localizing to specific organelles, facilitating and triggering chemical reactions, binding to other functional polypeptides.
- heterologous refers to the context of genetically modified host cells and refers to a polypeptide for which at least one of the following claims applies: (a) the polypeptide is foreign ("exogenous") to the host cell (it is not naturally present within the cell); (b) the polypeptide is naturally present ("endogenous") in a given host microorganism or host cell, but is produced in an unnatural amount in the cell (more than expected or in greater amounts than found in nature) or is differentiated in the nucleotide sequence from the endogenous nucleotide sequence, so that the same protein (having the same or substantially similar amino acid sequence) as the endogenous protein is produced in unnatural amounts (more than expected or more than found in nature) in the cell.
- homologous refers to proteins or nucleic acids with a well-conserved amino acid or nucleotide sequences, preferably with at least 50% conservation and no less than 20% conservation, determined by protein or nucleic acid comparative techniques known to experts in the field.
- homologous nucleic acids encode homologous proteins.
- a particular nucleic acid (DNA or RNA) is a product of various combinations of cloning, restriction and / or ligation leading to a construct having structurally coding or non-coding sequences different from endogenous nucleic acids in a natural host system.
- a DNA sequence encoding a structurally coding sequence may be formed from cDNA fragments, from short oligonucleotide linkers or from synthetic oligonucleotides from which a synthetic nucleic acid is obtained which can be expressed on a recombinant transcription unit in a cellular or cell- free transcription and translation system.
- Such a sequence can be used in the form of an open reading frame in which there is no interference from the internal non-translated sequences (introns) which are usually present in eukaryotic genes.
- Genomic DNA which contains important sequences can also be used to form a recombinant gene or transcription unit.
- Sequences of untranslated DNA may be present at the 5'- or 3'-end of the open reading frame, where such sequences do not affect the manipulation or expression of the coding regions and can act as modulators for the production of desired products through various mechanisms.
- the insertion of the vectors into the host cells is carried out by conventional methods known from the field of science, and the methods relate to transformation or transfection and include: chemically induced insertion, electroporation, micro-injection, DNA lipofection, cellular sonication, gene bombardment, viral DNA input, as well as other methods.
- the entry of DNA may be of transient or stable.
- Transient refers to the insertion of a DNA with a vector that does not incorporate the DNA of the invention into the cell genome.
- a stable insertion is achieved by incorporating DNA of the invention into the host genome.
- the insertion of the DNA of the invention in particular for the preparation of a host organism having stably incorporated DNA of the invention, can be screened by the presence of markers.
- the DNA sequence for markers refers to resistance to antibiotics or chemicals and may be included on a DNA vector of the invention or on a separate vector.
- Example 1 Preparation of cells, which feature a signaling pathway mediated by split proteases
- DNA constructs Preparation of DNA records for orthogonal split proteases and their targets.
- the inventors used molecular biology methods such as: chemical transformation of competent E. coli cells, plasmid DNA isolation, polymerase chain reaction (PCR), reverse transcription - PCR, PCR linking, nucleic acid concentration determination, DNA agarose gel electrophoresis, isolation of fragments of DNA from agarose gels, chemical synthesis of DNA, DNA restriction with restriction enzymes, cutting of plasmid vectors, ligation of DNA fragments, purification of plasmid DNA in large quantities.
- PCR polymerase chain reaction
- PCR reverse transcription -PCR
- PCR linking nucleic acid concentration determination
- DNA agarose gel electrophoresis isolation of fragments of DNA from agarose gels
- chemical synthesis of DNA DNA restriction with restriction enzymes
- cutting of plasmid vectors ligation of DNA fragments
- purification of plasmid DNA purification of plasmid DNA in large quantities.
- the proteases were selected from the proteases of the NIa family of potivirus proteins, specifically the SuMMV, SbMV, PPV and TEV proteases. Cleavage sequences for each of the described proteases are known to experts in the field. Based on the amino acid sequence similarity between these proteases and the already known sequence of split TEV protease, we prepared nucleotide transcripts for split proteases in fusion with dimerization domains.
- the light-induced domains of CRY2 and CIBN (Kennedy et al., 2010) and the rapamycin inducible domains of FKBP and FRB were selected as dimerization domains (Sabatini et al., 1994; Brown et al., 1994; Sabers et al., 1995).
- Table 1 List of sequences of split proteases that were used to illustrate the invention and their recognizable cleavage sites
- Table 2 Split proteases with dimerization domains that were used to illustrate the invention.
- Table 3 Fusion proteins and operones which were used, appart from the split proteases, to illustrate the invention.
- Cells from the HEK293T cell line were grown at 37 ° C and 5% C02.
- a DMEM medium containing 10% FBS was used, containing all the necessary nutrients and growth factors.
- the cells were grafted into a new breeding flask and / or diluted.
- the number of cells was determined by a hemocytometer and seeded in density 2.5xl0 4 per hole into the microtiter plate with 96 holes 18-24 hours before transfection.
- the seeded plates were incubated at 37 ° C and 5% C02 until the cells were 50-70% confluent and ready for transfection by transfection reagent.
- the transfection was carried out according to the instructions of the transfection reagent manufacturer (e.g., JetPei, Lipofectamine 2000) and was adapted for the microtiter plate used.
- Example 2 Catalytic activity of split proteases in mammalian cells at stimulation with various signals and orthogonality of cleavage with individual protease Cyclic firefly luciferase Flue based reporter system (Kanno et al. 2007) was used to detect catalytic activity of examined proteases. Cyclic luciferase, used as a reporter protein, was prepared by reorganizing amino acid sequence of firefly luciferase. Amino acids 4-233 from N-terminus were placed downstream to the C-terminus, connecting the two domains by a short linker which contains cleavage site for one of the following proteases: TEV, PPV, SuMMV or SbMV.
- the newly prepared protein was further modified by fusing two fragments of an intein via short linker to the ends, namely C-fragment of intein DnaE from organism Nostoc punctiforme was fused to N-terminus and N-fragment of intein DnaE from organism N. punctiforme to the C-terminus followed by amino acid sequence of peptide PEST-CL1 for fast digestion of the protein, previously known to experts from this field of science.
- Prepared luciferase based reporter thus forms inactive cyclic proteins, which can be cleaved with a target protease, resulting in structural reorganization and gain of luciferase catalytic activity.
- HEK293T cells implanted in 96-well plates, were transfected one day prior to the experiment with plasmids, which encode for one of examined proteases or two proteins, that combined form an active split protease; plasmids that encode previously described cyclic luciferase as a reporter protein and plasmid that encodes for luciferase from organism Renilla reniformis Rluc (GenBank AF362545.1).
- Cells were stimulated by addition of rapamycin to end concentration of 1 ⁇ one day prior to measurement or with light beam (455 nm wavelength) in specially prepared machine 30min prior to measurement.
- protease-cleavage- dependentTAL (N) -VP16-TEVs-KRAB transcription factor in addition to cyclic luciferase.
- the transcription factor was prepared in such a way that the sequence for the VP 16 activation domain was aded at the C-terminus of the TAL DNA binding domain, which is well known to the field experts, followed by a binding peptide with a recognizable sequence for cleavage with the TEV protease and the repressive domain KRAB.
- the VP16 and KRAB domains are also well-known to the field experts.
- the transcription factor changes the mode of action from repression to activation of the transcription of genes.
- a gene for the yellow fluorescence protein mCitrine was inserted into the plasmid after a minimal promoter with binding sites for the DNA-binding TAL domain.
- the HEK293T cells implanted in 96-hole plates, were transfected one day before the experiment with plasmids bearing cyclic luciferase code with a recognizable cleavage site with PPV protease, a transcription factor TAL (N) -VP16-TEVs-KRAB, mCitrin under the appropriate promoter and a code for luciferase Rluc, as well as plasmid with a TEV or PPV protease code as marked.
- TAL transcription factor TAL
- the media was removed from the cells and then measured by a fluorescence reader of SynergyMX plates (manufactured by BioTek) with excitation at the wavelength of 512 nm and an emission at the wavelength of 532 nm. The fluorescence of untransfected cells was subtracted from the value obtained.
- the reaction cyclic luciferaseprotein activity the cells were lysed with buffer according to the manufacturer's instructions (Promega) and then the activity of FLuc and Rluc was measured as in the above experiment.
- Logical functions NOR and A NIMPLY B have been developed as examples of the logical circuit with the transmission of the signal with proteases, the latter being the equivalent composite logic function A AND NOT B.
- a split luciferase rapporteur was used, which is comprised of an N-terminal luciferase fragment linked via a cleavage site for the TEV protease with an AP4 peptide and a C -terminal luciferase fragment, which is coupled via a cleavage site for the PPV protease with the peptide P3.
- Peptides P3 and AP4 form a coiled coil, which allows for the reconstitution of luciferase fragments into an active enzyme.
- the HEK293T cells in the 96-hole plate were transfected one day before the experiment with plasmids bearing the Rluc luciferase, the nLuc-TEVs-AP4 and P3-PPVs-cLuc luciferase, and plasmids with TEV protease and PPV protease as marked.
- the activity of the reporting proteins Flue and Rluc was measured as described above. Result:From Fig. 5B it can be seen that we observed a decrease in the activity of the reporter when coexpressed with any of the selected proteases. This is in line with the expected function of the NOR function.For the function A NIMPLY B (Fig.
- a split protease reporter was also used, but in this case it consists of an N-terminal luciferase associated with the peptide AP4, which is further linked to the P4mS peptide by the cleavage site for the TEV protease.
- a C-terminal luciferase fragment bound to the P3 peptide via the cleavage site for the PPV protease was added to the system as well.
- the peptides AP4 and P3mS form a coiled coil, which prevents the formation of a coiled coil between AP4 and P3 and thus the reconstitution of the functional luciferase enzyme.
- the formation of a coiled coil between AP4 and P3mS destabilizes as it cleaves the connecting peptide between them. Since the peptide P3 forms a more stable coiled coil with AP4, now there may be reconstitution of luciferase, but only in the absence of PPV protease, since it cleaves the C- terminal luciferase fragment from P3 peptide. The outcome signal (activity of luciferase) can therefore be detected only when cleavage with TEV protease and absence of cleavage with PPV protease.
- the HEK293T cells in the 96-hole plates were transfected one day before the experiment with plasmids bearing the Rluc luciferase, the nLuc-AP4-TEVs-P3mS and P3-PPVs-cLuc reporting protein, plasmids with split TEV with inducible CRY2 and CIBN domains, and plasmids bearing splice-protected PPV proteases with inducible FKBP and FRB domains.
- the cells were stimulated by the addition of rapamycin to a final concentration of 1 ⁇ or with light with a wavelength of 455 nm 15 minutes before the measurement in a specially prepared device. The activity of the reporting Flue and Rluc protein was measured as described above.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SI201600252A SI25289A (sl) | 2016-10-12 | 2016-10-12 | Kombinacija razcepljenih ortogonalnih proteaz z dimerizacijskimi domenami, ki omogočajo sestavljanje |
PCT/IB2017/055902 WO2018069782A2 (fr) | 2016-10-12 | 2017-09-27 | Combinaison de protéases orthogonales dédoublées présentant des domaines de dimérisation permettant un assemblage |
Publications (1)
Publication Number | Publication Date |
---|---|
EP3526325A2 true EP3526325A2 (fr) | 2019-08-21 |
Family
ID=60268416
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP17794772.8A Withdrawn EP3526325A2 (fr) | 2016-10-12 | 2017-09-27 | Combinaison de protéases orthogonales dédoublées présentant des domaines de dimérisation permettant un assemblage |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP3526325A2 (fr) |
SI (1) | SI25289A (fr) |
WO (1) | WO2018069782A2 (fr) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3701015B1 (fr) * | 2017-10-24 | 2022-04-06 | Ulisse Biomed S.P.A. | Système de nanocommutateur d'amplification basé sur des enzymes de clivage spécifiques à un site fractionné permettant la détection in vitro d'analytes cibles et procédé permettant la détection desdits analytes cibles |
EP3740231A4 (fr) | 2018-01-18 | 2022-03-23 | California Institute of Technology | Circuits de protéines programmables dans des cellules vivantes |
US11965191B2 (en) | 2018-01-18 | 2024-04-23 | California Institute Of Technology | Programmable protein circuits in living cells |
US11453893B2 (en) | 2018-08-30 | 2022-09-27 | California Institute Of Technology | RNA-based delivery systems with levels of control |
WO2020047320A1 (fr) * | 2018-08-31 | 2020-03-05 | California Institute Of Technology | Circuits de protéine synthétique permettant de détecter une activité de transducteur de signal |
US11667676B2 (en) | 2019-01-10 | 2023-06-06 | California Institute Of Technology | Synthetic system for tunable thresholding of protein signals |
EP3783104A1 (fr) * | 2019-08-20 | 2021-02-24 | Kemijski Institut | Connexion à médiation de superhélice de crispr-cas et d'exonucléases pour améliorer l'édition de génomes |
IT202000018064A1 (it) * | 2020-07-27 | 2022-01-27 | Univ Cattolica Del Sacro Cuore | Sviluppo di una nuova proteasi tobacco etch virus (tev) ingegnerizzata attivabile nel citosol o nel pathway secretorio |
CN112921053B (zh) * | 2021-02-02 | 2023-04-14 | 汕头大学 | 一种可追踪细胞分化发育的双重诱导mCreER系统及其建立与应用 |
CN114591442B (zh) * | 2022-03-01 | 2024-04-19 | 中国科学院深圳先进技术研究院 | 一种受光调控的蛋白酶工具及其配套底物 |
WO2024011146A1 (fr) * | 2022-07-06 | 2024-01-11 | California Institute Of Technology | Réseau neuronal de niveau de protéine synthétique dans des cellules de mammifère |
US20240124913A1 (en) * | 2022-10-14 | 2024-04-18 | California Institute Of Technology | Protein-Based Signal Amplification |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9791436B2 (en) * | 2012-09-12 | 2017-10-17 | The University Of Queensland | Protease-based biosensor |
US9772328B2 (en) * | 2013-09-12 | 2017-09-26 | The University Of Queensland | Bimolecular protease-based biosensor |
-
2016
- 2016-10-12 SI SI201600252A patent/SI25289A/sl not_active IP Right Cessation
-
2017
- 2017-09-27 EP EP17794772.8A patent/EP3526325A2/fr not_active Withdrawn
- 2017-09-27 WO PCT/IB2017/055902 patent/WO2018069782A2/fr unknown
Also Published As
Publication number | Publication date |
---|---|
WO2018069782A3 (fr) | 2018-05-24 |
WO2018069782A2 (fr) | 2018-04-19 |
SI25289A (sl) | 2018-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2018069782A2 (fr) | Combinaison de protéases orthogonales dédoublées présentant des domaines de dimérisation permettant un assemblage | |
Wood et al. | Intein applications: from protein purification and labeling to metabolic control methods | |
Topilina et al. | Recent advances in in vivo applications of intein-mediated protein splicing | |
US10221422B2 (en) | Blue light-inducible system for gene expression | |
CA3012607A1 (fr) | Enzymes et systemes crispr | |
Heikkila et al. | Heat shock protein gene expression during Xenopus development | |
CN112004932B (zh) | 一种CRISPR/Cas效应蛋白及系统 | |
US20040146889A1 (en) | Inducible regulatory system and use thereof | |
Schuelein et al. | Targeting of RNA Polymerase II by a nuclear Legionella pneumophila Dot/Icm effector SnpL | |
EP0626450A2 (fr) | Protéines de fusion contenant l'enzyme conjugant l'ubiquitine (E2) | |
CA2574540A1 (fr) | Rapport de lignee cellulaire dans un cycle cellulaire comprenant un domaine de localisation sous-cellulaire phosphoryle de l'adn helicase b humaine | |
Wang et al. | Association of rabbit sperm cells with exogenous DNA | |
KR20210062639A (ko) | 신규 뉴클레아제 도메인 및 그 이용 | |
CN110747199B (zh) | 蜜蜂抗逆相关基因nf-y及其应用 | |
JP2023036848A (ja) | 凝集の少ないpprタンパク質及びその利用 | |
CA3181824A1 (fr) | Modules riboregulateurs et procedes de commande d'expression proteique dans les plantes | |
US20240093206A1 (en) | System of stable gene expression in cell lines and methods of making and using the same | |
TW200411069A (en) | Detection of evolutionary bottlenecking by dna sequencing as a method to discover genes of value | |
EP4308597A1 (fr) | Techniques de génie pour des actionneurs protéiques fragmentés inductibles chimiquement (cispa) | |
US20060019238A1 (en) | Method for identifying protein-protein interactions | |
KR20210016509A (ko) | 유전자 발현을 제어하기 위한 방법 | |
Vee | Regulation of ribonucleotide reductases in growth and development in the social amoebae Dictyostelium discoideum | |
WO2019090287A2 (fr) | Systèmes de détection de séquence | |
Byczko | Gene activation potential of MsHsfA4, a heat shock transcription factor from Medicago sativa L. | |
Stephenson | 19 Yeast Two‐Hybrid Studies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20190510 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20200806 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20221028 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20230308 |